Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells-Reference-Cited by-同舟云学术

Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells

Published:2017-12-11 Issue:2 Volume:48 Page:330-343
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Loeschenberger Beatrix¹,Niess Lea¹,Würzner Reinhard²,Schwelberger Hubert³,Eder Iris E.⁴,Puhr Martin⁴,Guenther Julia⁵,Troppmair Jakob⁵,Rudnicki Michael¹,Neuwirt Hannes¹^ORCID

Affiliation:

1. Department of Internal Medicine IV; Innsbruck Medical University; Innsbruck Austria

2. Division of Hygiene and Medical Microbiology; Innsbruck Medical University; Innsbruck Austria

3. Molecular Biology Laboratory; Department of Visceral; Transplant and Thoracic Surgery; Innsbruck Medical University; Innsbruck Austria

4. Department of Urology; Division of Experimental Urology; Innsbruck Medical University; Innsbruck Austria

5. Daniel Swarovski Research Laboratory; Department of Visceral; Transplant- and Thoracic Surgery; Innsbruck Medical University; Innsbruck Austria

Funder

Medizinischer Forschungsfonds Tirol Kliniken

Austrian Science Fund

Tiroler Wissenschaftsfonds

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Reference68 articles.

1. Long-term renal allograft survival in the United States: a critical reappraisal;Lamb;Am. J. Transplant.,2011

2. Immunosuppression modification by everolimus with minimization of calcineurin inhibitors recovers kidney graft function even in patients with very late conversion and also with poor graft function;Nojima;Transplant. Proc.,2017

3. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study);Durrbach;Am. J. Transplant.,2010

4. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study;Rostaing;Clin J Am Soc Nephrol,2011

5. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study);Vincenti;Am. J. Transplant.,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corneal application of SOCS1/3 peptides for the treatment of eye diseases mediated by inflammation and oxidative stress;Frontiers in Immunology;2024-07-22

2. A local drug delivery system prolongs graft survival by dampening T cell infiltration and neutrophil extracellular trap formation in vascularized composite allografts;Frontiers in Immunology;2024-06-03

3. Progressive Hereditary Transthyretin-Related Amyloidosis (ATTRv) Aggravated by ATTR Wild-Type and Complement Activation;Journal of Neuropathology & Experimental Neurology;2022-01-29

4. Impact of the ACE2 activator xanthenone on tacrolimus nephrotoxicity: Modulation of uric acid/ERK/p38 MAPK and Nrf2/SOD3/GCLC signaling pathways;Life Sciences;2022-01

5. Complement Components in the Diagnosis and Treatment after Kidney Transplantation—Is There a Missing Link?;Biomolecules;2021-05-21